Table 7.
Comparison of dosage formulations
| Formulation | Drug concentration (μg/ml) | p |
|---|---|---|
| Posaconazole | ||
| Delayed-release tablet (median [IQR]) | 1.48 (0.76–2.21) | <0.01 |
| IV (median [IQR]) | 1.74 (1.47–2.56) | |
| Oral suspension (median [IQR]) | 0.40 (0.17–0.95) | |
| Voriconazole | ||
| IV (median [IQR]) | 3.31 (1.41–5.70) | <0.01 |
| PO (median [IQR]) | 1.78 (0.84–4.00) | |
| Therapeutic drug level | Non-therapeutic drug level | OR (95% CI) | p | |
|---|---|---|---|---|
| Posaconazole | (n = 69) | (n = 31) | ||
| Delayed-release tablet | 27/33 (82%) | 6/33 (18%) | 7.7 (2.6–23.2)a | <0.01 |
| IV | 28/29 (97%) | 1/29 (3%) | 48 (5.9–392.3)a | <0.01 |
| Oral suspension | 14/38 (37% | 24/38 (63%) | ||
| Voriconazole | (n = 134) | (n = 116) | ||
| IV (no. [%]) | 56 (42) | 50 (43) | 1.06 (0.64–1.74) | 0.90 |
| PO (no. [%]) | 78 (58) | 66 (57) |
IQR interquartile range, OR odds ratio, CI confidence interval
aIn reference to posaconazole oral suspension